ESMO 2014: Selected Abstract Sessions
Researchers submitted 2,746 abstracts to this year’s congress, representing an increase of almost 24% compared to ESMO 2012 in Vienna.
Below, we’ve made a small selection of regular abstract sessions from several different tumour types. All titles and authors of regular abstracts can now be found on the online programme.
More news on Late-breaking abstracts following the final submission deadline of 20 August.
Presidential Symposium 1
Sunday 28 September 2014, 16:00-18:00
- View Presidential Symposium 1 in the online programme
- View Presidential Symposium 2 in the online programme
Final overall survival (OS) analysis from the CLEOPATRA study of first-line (1L) pertuzumab (Ptz), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC).
Discussant: S. Swain, US
MAGRIT, a double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of the recMAGE-A3 + AS15 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small cell lung cancer (NSCLC).
Discussant: F. Vansteenkiste, BE
Proffered Paper Session: Melanoma and other skin tumours
Saturday 27 September 2014, 14:00-15:45
Survival, response duration, and activity by BRAF mutation (MT) status in a phase 1 trial of nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).
Discussant: H. Kluger, US
Proffered Paper Session: Neuroendocrine tumours
Saturday 27 September 2014, 11:00-12:30
Everolimus (EVE) for the Treatment of Advanced Pancreatic Neuroendocrine Tumours (pNET): Final Overall Survival (OS) Results of a Randomized, Double-blind, Placebo (PBO)-Controlled, Multicenter Phase III Trial (RADIANT-3).
Discussant: J.C. Yao, US
Proffered Paper Session: Gastrointestinal tumours, colorectal
Saturday 27 September 2014, 08:45-10:45
Bevacizumab-Erlotinib as maintenance therapy in metastatic colorectal cancer. Final results of the GERCOR DREAM study.
Discussant: B. Chibaudel, FR
Maintenance strategy with fluoropyrimidines (FP) plus bevacizumab (Bev), Bev alone or no treatment, following a 24-week first-line induction with FP, oxaliplatin (Ox) and Bev for patients with metastatic colorectal cancer: Mature data and subgroup analysis of the AIO KRK 0207 phase III study.
Discussant: S. Hegewisch-Becker, DE
Proffered Paper Session: NSCLC, locally advanced and metastatic
Monday 29 September 2014, 10:45-12:30
Final results of the SAKK 16/00 trial: a randomized phase III trial comparing neoadjuvant chemoradiation to chemotherapy alone in stage IIIA/N2 non-small cell lung cancer (NSCLC).
Discussant: M.Pless, CH
Proffered Paper Session: NSCLC, metastatic 2
Sunday 28 September 2014, 09:15-10:30
Overall and intracranial (IC) efficacy results and time to symptom deterioration in PROFILE 1014: 1st-line crizotinib vs pemetrexed−platinum chemotherapy (PPC) in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC).
Discussant: B. Solomon, AU
Proffered Paper Session: Sarcoma
Monday 29 September 2014, 15:45-17:30
Outcome of first-line treatment of elderly advanced soft tissue sarcoma (STS) patients: a pooled analysis of eleven EORTC Soft Tissue and Bone Sarcoma Group trials.
Discussant: W.T.A. van der Graaf, NL